p130

Contents: p130 (C20) Blocking Peptide
Catalog Number: 66-P745
Formulation: Each vial contains 100 μg of peptide in 0.5 ml PBS with 0.1% NaN₃ and 100 μg BSA.
Storage Conditions: Store at 4°C.
DO NOT FREEZE.

Prices for This Product*
Cat. No.	Size	Price	Qty	Action
66-P745-81	50 ug	$25

*International customers: Please contact your distributor for region specific pricing.

Available Formats of This Product
Cat. No.	Format	Excite (nm)	Emit (nm)	Reported Applications
66-P745	Blocking Peptides for anti-mouse/human/rat p130 polyclonal	N/A	N/A	WB

Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq.

Description

This is a peptide mapping to the carboxy terminal domain of human p130. The pocket protein family consists of three structurally and functionally related proteins, Rb, p107, and p130 (1). This family of tumor suppressors function to regulate important cellular transcription factors, such as the E2F family (1,2). The E2F proteins regulate the expression of genes whose products are important for cell cycle progression. The inactivation Rb is catalyzed by CDK phosphorylation thereby releasing E2F during the G1-S phase cellular progression (3). Unchecked inactivation of Rb in G1 phase has been indicated as a universal mechanism underlying cellular transformation (4,5). While Rb has been the most studied among the pocket proteins, p107 and p130 have also been shown to be key regulators of E2F (6). Several studies have also provided evidence that p107/p130 provide different functions in E2F regulation than does Rb (6,7). Rb, p107, and p130 each contain a conserved ?A/B pocket?, which is the target of several viral oncoproteins, namely SV40 large T-antigen and adenovirus E1A (8).

Applications Reported

For research use only, not for diagnostic or therapeutic use. This blocking peptide has been reported for use in competition studies.

References

1. Halaban R. 1999. Melanoma cell autonomous growth: the Rb/E2F pathway. Cancer Metastasis Rev 18(3):333-343.
2. Sidle A., Palaty C., Dirks P., Wiggan O., Kiess M., Gill R.M., Wong A.K., Hamel P.A. 1996. Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. Crit Rev Biochem Mol Biol 31(3):237-271.
3. Classon M., Dyson N. 2001. p107 and p130: versatile proteins with interesting pockets. Exp Cell Res 264(1):135-147.
4. Hatakeyama M., Weinberg R.A. 1995. The role of RB in cell cycle control. Prog Cell Cycle Res 1:9-19.
5. Nevins J.R. 2001. The Rb/E2F pathway and cancer. Hum Mol Genet 10(7):699-703.
6. Hurford R.K., Cobrinik D., Lee M.H., Dyson N. 1997. pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev 11(11):1447-1463.
7. Smith E.J., Leone G., Nevins J.R. 1998. Distinct mechanisms control the accumulation of the Rb-related p107 and p130 proteins during cell growth. Cell Growth Differ 9(4):297-303.
8. Knudsen E.S., Wang J.Y. 1998. Hyperphosphorylated p107 and p130 bind to T-antigen: identification of a critical regulatory sequence present in RB but not in p107/p130. Oncogene 16(13):1655-1663.

Related Products

Cat. 14-6745 Purified anti-mouse/human/rat p130 polyclonal (clone Polyclonal)